Fitzsimons Innovation Community is an integrated urban campus where health and life sciences companies of all sizes work on their next big things. Our customized workspace, collaborative campus, and proximity to one of the top health systems and medical schools in the country make our community the perfect place to put down roots and get to work.
MOVE-IN READY LAB SPACE
GROWTH OPPORTUNITIES
Coming soon
It’s not just additional space—it’s fifty sprawling acres of additional space. And it’s primed for ultra-custom, made-to-order facility development.
Fitzsimons Innovation Community and University of Colorado Anschutz Medical Campus working together.
Relationships that help you thrive.
An urban mountain lifestyle for work and play.
Everything you need.
Right here.
Read Fitzsimons Innovation Community news, industry highlights, editorials, and innovation updates happening weekly on our campus.
Ideas become cures when academia and industry connect. When you talk to Terry Fry, M.D., about why the Gates Institute is one of the best locations in the country to work in cellular and gene therapy, he has a lot of insight. As the executive director of the Gates Institute, a pediatric oncologist, and a pioneer in the development of chimeric antigen receptor (CAR)-T cell therapies, Dr. Fry has an intimate understanding of what it takes to get a drug from initial research phases to commercial manufacturing. And often what it takes is the right facilities with the right partners working together at each stage of development.
The life sciences ecosystem in Colorado has experienced tremendous growth over the past decade, and the momentum will continue to build. The region is on a trajectory to crack the top five innovation hubs in the country with competitive advantages that favor life sciences. To get there, we must continue to collaborate to attract national and international biotech companies to Colorado for the long-term.
Fitzsimons Innovation Community releases its Second Annual Innovation Report focused on the momentum our Community members build on our campus to take their discoveries and projects from idea to market.
The company’s off-the-shelf or ‘allogeneic’ therapy tabelecleucel – now given the Ebvallo trade name – has been approved by the European Commission as a second-line treatment for a rare and potentially deadly cancer that afflicts some organ or bone marrow transplant recipients.
The University of Colorado Anschutz Medical Campus has been named one of the top academic institutions in the world for innovation, according to Nature’s 2022 Innovation Index report. The report ranked CU Anschutz in the top four universities globally for forging the strongest innovations links.
Colorado BioScience Association today announced annual fundraising totals for the state’s life sciences ecosystem. Companies, organizations, and researchers in the state’s life sciences community raised $1.6 billion in 2022, marking the sixth year fundraising totals hit more than $1 billion. The numbers are consistent with life sciences funding trends across the U.S., with activity remaining strong but returning to pre-pandemic levels following a record-breaking 2021.
Bringing together industry partners, entrepreneurs, and investors to help CU researchers and healthcare practitioners solve important medical problems and improve the quality of life for patients worldwide. We strive to enable healthcare advancements and scientific research that will benefit society, while also generating a sustainable revenue stream for the University.
A conversation with Melissa Krebs, CEO and Founder of GelSana and Associate Professor at Colorado School of Mines.
The award recognizes the investments Fitzsimons Innovation Community is making to advance Colorado’s life sciences community and better position the entire ecosystem for growth
Congresswoman Diana DeGette (D-CO) visits the Gates Biomanufacturing Facility's Protein Suite, in which GMP-grade AV-1980R was manufactured for the Institute for Molecular Medicine's phase 1 clinical...
Explore how Atara's investigational EBV T-cell platform-based therapies target cancer and autoimmune diseases are manufactured.
Fitzsimons Innovation Community
